Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference

Rhea-AI Summary

Baird Medical Investment Holdings (NASDAQ: BDMD), a leading microwave ablation (MWA) medical device developer and provider in China, has announced its participation in Roth's 3rd Annual Healthcare Opportunities Conference on October 9, 2024, in New York City. The company's management plans to host one-on-one and small group meetings with institutional investors at the event.

This participation comes as Baird Medical expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology. The company's technology offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed annually in the United States.

Baird Medical's expansion into the U.S. market follows its receipt of US FDA 510(k) clearances, positioning the company to tap into a significant market opportunity in thyroid tumor treatment.

News Market Reaction – BDMD

+1.42%

+1.42% Session move

In the trading session that priced this news, BDMD gained 1.42%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GUANGZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced that the Company will participate in the following investor conference. Baird Medical's management plans to host one-on-one and small group meetings with institutional investors at the conference.

Roth's 3^rd Annual Healthcare Opportunities Conference
Wednesday, October 9, 2024
Metropolitan Club, 1 E 60^th Street, New York, NY, 10022

Baird Medical's participation in the event comes as the Company expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology, which offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed in the U.S. annually.

About Baird Medical

Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China and a recent entrant to the United States market. Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung nodules and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://www.bairdmed.com/.

Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com

Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com

 

 

View original content:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-roths-3rd-annual-healthcare-opportunities-conference-302270307.html

SOURCE Baird Medical Investment Holdings Ltd.

FAQ

When and where is Baird Medical (BDMD) participating in Roth's 3rd Annual Healthcare Opportunities Conference?

Baird Medical (BDMD) is participating in Roth's 3rd Annual Healthcare Opportunities Conference on Wednesday, October 9, 2024, at the Metropolitan Club, 1 E 60th Street, New York, NY, 10022.

What recent regulatory approval has Baird Medical (BDMD) received for the U.S. market?

Baird Medical (BDMD) has recently received US FDA 510(k) clearances for its minimally invasive microwave ablation technology, allowing the company to expand into the U.S. market.

How many thyroidectomies are performed annually in the U.S., according to Baird Medical's (BDMD) press release?

According to the press release, 150,000 thyroidectomies are performed annually in the United States.

What alternative does Baird Medical (BDMD) offer for thyroid tumor treatment?

Baird Medical (BDMD) offers minimally invasive microwave ablation technology as a promising alternative to thyroidectomy for patients with benign thyroid tumors.